Trump funding cuts harming HIV patients, WHO says

• The World Health Organization (WHO) warns that cuts to USAID funding for HIV/AIDS programs, initiated by the Trump administration, are causing drug shortages and increasing the risk of drug resistance.
• Millions of people, particularly in sub-Saharan Africa, rely on dolutegravir (DTG), a crucial HIV drug now in short supply. Experts predict a significant rise in drug resistance if shortages continue, jeopardising long-term HIV control.
• The WHO expresses concern about the lack of a readily available, affordable, and equally effective alternative to DTG, especially for vulnerable populations like children and pregnant women.
• The funding cuts have led to clinic closures and treatment interruptions, exacerbating the risk of infections and drug-resistant strains.
• While the US State Department claims that life-saving HIV services are ongoing and under review, there's no confirmation of funding restoration, leaving millions at risk.

IN FULL

WHO warns Trump cuts put millions of HIV patients at risk